Compare Genuine Parts Company (GPC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Twist Bioscience Corp — how do they compare? Genuine Parts Company trades at $125.06 (market cap $16.65B), while Twist Bioscience Corp trades at $89.93 (market cap $5.76B). The key difference: Genuine Parts Company is far larger — about 2.9× Twist Bioscience Corp's market cap, and Genuine Parts Company pays a 3.51% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| GPC | TWST | |
|---|---|---|
Market Cap | $16.65B | $5.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $102.88 |
52-Week Low | $92.47 | $24.16 |
Enterprise Value | $22.87B | $5.69B |
Dividend Yield | 3.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.40, up 2.65% with a bullish technical signal. The stock shows mixed fundamentals with a high P/E ratio of 275 but strong gross margins of 36.87%. Recent earnings beat expectations in Q1 2026 after two consecutive misses, with Q2 2026 results expected July 21. Analyst consensus is mixed with 43% buy ratings and a $133 price target, while technical indicators show support at $119-120 and resistance at $122-124.
GPC presents a cautious opportunity with dividend stability but faces profitability challenges. The 70-year dividend growth history provides income appeal, though net margins below 1% and declining cash flow trends warrant monitoring. Upside exists if Q2 earnings beat expectations, but weak profitability and rising debt-to-asset ratios pose significant risks to shareholder value.
Twist Bioscience (TWST) trades at $90.33, down 2.46% on the day, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst sentiment is positive with 11 buy ratings and a $91.63 consensus target, while recent news highlights AI collaborations and upcoming Q3 earnings.
TWST presents a growth story with improving margins and AI-driven demand, but profitability concerns and consistent cash burn pose risks. The stock trades near analyst targets, suggesting limited near-term upside without earnings acceleration. Key catalysts include Q3 results on August 3, 2026, and execution on path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
